## **MPACT** of Inflammatory Bowel Diseases (IBD)


EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS (EFCCA)

**MAY 2014** 

## **TREATMENT**

## **IMPACT** on treatment

- → Evidence for treatment plan (anti-TNF and surgery)
- Access to biological therapy is becoming more established, but a majority of patients has used corticosteroids, experienced side effects, and are concerned about longterm effects (see Figure)



## **EFCCA** recommends:

- Maintain and develop good IBD health-service standards, in line with published guidelines www.ibdstandards.org.uk
- High hospital admission represents a poor patient experience, an urgent opportunity for improvement, and significant morbidity. Reducing this burden may somewhat counterbalance the cost of new IBD treatments it may pay to treat with innovative therapies
- Ensure that use of corticosteroids is in line with ECCO guidelines, and that the full range of treatment options is considered, according to comparative risk-benefit profiles

